Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 13,176 shares, a decline of 63.4% from the January 15th total of 35,983 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 89,790 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 89,790 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

FSNUY has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Monday, October 27th. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Fresenius SE & Co. Stock Down 0.2%

Shares of FSNUY opened at $14.92 on Wednesday. The firm has a market cap of $33.61 billion, a P/E ratio of 27.13 and a beta of 0.75. Fresenius SE & Co. has a 12 month low of $9.54 and a 12 month high of $33.93. The stock’s 50 day moving average is $14.29 and its two-hundred day moving average is $14.18. The company has a current ratio of 1.26, a quick ratio of 0.99 and a debt-to-equity ratio of 0.49.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.